ClinicalTrials.gg
TerminatedNCT02372578Updated Mar 26, 2019

Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

A Phase 2 interventional study of ASP3662 and pregabalin in Painful Diabetic Peripheral Neuropathy (PDPN), sponsored by Astellas Pharma Global Development, Inc.. Terminated at 37 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-03-26.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study was terminated due to futility analysis.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo.

The analgesic effect is evaluated by measuring percent responders, change in daily worst pain score, change in average daily pain score, Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC).

02

Conditions studied

  • Painful Diabetic Peripheral Neuropathy (PDPN)

Keywords

  • Painful diabetic peripheral neuropathy (PDPN)
  • ASP3662
03

In context

Lead sponsor

Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.

Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has a ≤ 40.
  • Subject has all of the following:

    1. Established diagnosis of diabetes (Type I or II) with painful diabetic peripheral neuropathy and glycosylated (HgbA1c) ≤ 9.5% at Screening or Randomization.
    2. Stable diabetic drug regimen for at least 3 months prior to Screening.
    3. At least a 1 year history of PDPN.
    4. Diagnosis of PDPN to be confirmed by a score of ≥ 3 on the Michigan Neuropathy Screening Instrument (MNSI) at Screening.
  • Subject has pain intensity score(s) ≥ 4 or ≤ 9 on an 11-point numeric pain rating scale (NPRS) at Screening Visit and prior to Randomization.
  • Subject agrees to complete pain diaries and is complaint with the daily pain recording prior to Randomization as defined by the completion of a minimum of 5 of 7 daily pain ratings, 3 of which are required in the last 4 days.
  • Subject's anti-diabetic regimen is anticipated to be stable throughout the study.
  • Subject must be willing to washout of all medications currently being taken for his/her PDPN (chronic and occasional/as needed) and remain off of those pain medications while participating in the study.

Exclusion criteria

Exclusion Criteria:

  • Subject has received prior treatment with pregabalin for PDPN and was considered unresponsive or intolerant.
  • Subject has tried and failed 3 or more drugs to treat PDPN within the past 3 years. Drugs must have been administered at therapeutic doses and have been administered for an adequate period of time.
  • Subject has a known to ASP3662, pregabalin, gabapentin or acetaminophen, or their formulation components.
  • Subject has significant pain (moderate or above) due to causes other than PDPN.
  • Subject has a history of painful peripheral neuropathy due to a cause other than diabetes.
  • Subject has any lower extremity amputation
  • Subject has a current or previous foot ulcer within the past 3 months as described by medical history and/or medical examination.
  • Subject has an active or a history of malignancy (except for treated non-melanoma skin cancer) within 5 years.
  • Subject has abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine at Screening.
  • Subject has \< 60 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation) at Screening.
  • Subject tests positive for surface antigen (HBsAg) or antibody at Screening or has a known history of a positive test for (HIV) infection.
  • Subject has a positive drug screen for alcohol or drugs of abuse at Screening and/or Randomization. Subjects who are on low doses of benzodiazepines for sleep with a legitimate prescription will be allowed into the study. In addition, subjects with a positive drug screen at Randomization will be excluded.
  • Subject is currently using protocol specified non-permitted medications including OTC products and is unable or does not choose to discontinue them.
  • Subject has planned an elective surgery during planned study participation.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    ASP3662

    ASP3662 once daily (QD) and pregabalin placebo 3 times daily (TID) for Weeks 1 - 6. ASP3662 placebo QD and pregabalin placebo TID for Week 7.

    Drug: ASP3662 · Drug: ASP3662 placebo · Drug: pregabalin placebo

  • Active comparator
    pregabalin

    pregabalin TID and ASP3662 placebo QD for Weeks 1 - 7.

    Drug: pregabalin · Drug: ASP3662 placebo

  • Placebo comparator
    Placebo

    ASP3662 placebo QD and pregabalin placebo TID for Weeks 1 - 7.

    Drug: ASP3662 placebo · Drug: pregabalin placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change from Baseline in mean 24-hour average pain intensity as reported on the NPRS

    Numerical Pain Rating Scale (NPRS)

    Time frame: Baseline to Week 6/ End of Treatment (EOT)

Secondary outcomes

  1. Percentage of Responders in mean 24-hour average pain intensity score

    Time frame: Baseline to Week 6/ EOT

  2. Change from Baseline in mean of 24-hour average pain intensity score

    Time frame: Baseline to Weeks 1, 2, 3, 4, 5 and 6

  3. Change from Baseline in mean daily worst pain score

    Time frame: Baseline to Week 6/ EOT

  4. Change from Baseline in mean daily average pain score

    Time frame: Baseline to Week 6/ EOT

  5. Patient Global Impression Change (PGIC)

    Time frame: Week 6/ EOT

  6. Clinical Global Impression of Change (CGIC)

    Time frame: Week 6/ EOT

07

Study locations

37 sites
  • Site US10001
    Anniston, Alabama 36207, United States
  • Site US10039
    Phoenix, Arizona 85023, United States
  • Site US10054
    Fresno, California 93720, United States
  • Site US10020
    Lomita, California 90717, United States
  • Site US10047
    Santa Monica, California 90404, United States
  • Site US10017
    Tustin, California 92780, United States
  • Site US10055
    Walnut Creek, California 94598, United States
  • Site US10053
    Fairfield, Connecticut 06824, United States
  • Site US10005
    Boynton Beach, Florida 33436, United States
  • Site US10023
    Bradenton, Florida 34205, United States
  • Site US10018
    Clearwater, Florida 33765, United States
  • Site US10019
    DeLand, Florida 32720, United States
  • Site US10004
    Homestead, Florida 33030, United States
  • Site US10042
    Jacksonville, Florida 32256, United States
  • Site US10007
    Jupiter, Florida 33458, United States
  • Site US10041
    Miami Lakes, Florida 33014, United States
  • Site US10046
    Orlando, Florida 32806, United States
  • Site US10008
    Ormond Beach, Florida 32174, United States
  • Site US10003
    Oviedo, Florida 32765, United States
  • Site US10049
    The Villages, Florida 32162, United States
  • Site US10009
    Aurora, Illinois 60506, United States
  • Site US10036
    Chicago, Illinois 60624, United States
  • Site US10025
    Evansville, Indiana 47714, United States
  • Site US10064
    Metairie, Louisiana 70006, United States
  • Site US10051
    Boston, Massachusetts 02115, United States
  • Site US10026
    New Bedford, Massachusetts 02740-2133, United States
  • Site US10063
    Quincy, Massachusetts 02169, United States
  • Site US10043
    Hazelwood, Missouri 63042, United States
  • Site US10013
    Kettering, Ohio 45429, United States
  • Site US10014
    Duncansville, Pennsylvania 16635, United States
  • Site US10015
    Greer, South Carolina 29651, United States
  • Site US10034
    Austin, Texas 78731, United States
  • Site US10040
    Houston, Texas 77030, United States
  • Site US10032
    San Antonio, Texas 78218, United States
  • Site US10031
    San Antonio, Texas 78228, United States
  • Site US10033
    Salt Lake City, Utah 84107, United States
  • Site US10045
    Renton, Washington 98057, United States
08

References and documents

Individual participant data

Plan to share: Undecided — Studies conducted with product indications or formulations that remain in development are assessed after study completion to determine if Individual Participant Data can be shared. The plan to share Individual Participant Data is based on the status of product approval or termination of the compound, in addition to other study-specific criteria described on www.clinicalstudydatarequest.com under "Sponsor Specific Details for Astellas."

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2015 to primary completion in May 2016, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2015
First posted
Feb 26, 2015
StartActual
May 27, 2015
Primary completionActual
May 20, 2016
CompletionActual
May 20, 2016
Results delay requested
May 10, 2017
Last update
Mar 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02372578
Responsible party
Sponsor
First posted
Feb 26, 2015
Start date
May 27, 2015
Primary completion
May 20, 2016
Completion
May 20, 2016
Last update
Mar 26, 2019

Study contacts

Senior Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ASP3662

Start the discussion